These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice. Kassa J; Karasova J; Musilek K; Kuca K Toxicology; 2008 Jan; 243(3):311-6. PubMed ID: 18054821 [TBL] [Abstract][Full Text] [Related]
7. Relationships between the antidotal efficacy and structure, PK/PD parameters and bio-relevant molecular descriptors of AChE reactivating oximes: inclusion and integration to biopharmaceutical classification systems. Voicu V; Rădulescu FŞ; Medvedovici A Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):95-109. PubMed ID: 25373357 [TBL] [Abstract][Full Text] [Related]
8. Passive diffusion of acetylcholinesterase oxime reactivators through the blood-brain barrier: influence of molecular structure. Karasova JZ; Pohanka M; Musilek K; Zemek F; Kuca K Toxicol In Vitro; 2010 Sep; 24(6):1838-44. PubMed ID: 20546883 [TBL] [Abstract][Full Text] [Related]
9. The possible use of oximes as antidotal therapy in organophosphate-induced brain damage. Shrot S; Markel G; Dushnitsky T; Krivoy A Neurotoxicology; 2009 Mar; 30(2):167-73. PubMed ID: 19150463 [TBL] [Abstract][Full Text] [Related]
11. Suitability of human butyrylcholinesterase as therapeutic marker and pseudo catalytic scavenger in organophosphate poisoning: a kinetic analysis. Aurbek N; Thiermann H; Eyer F; Eyer P; Worek F Toxicology; 2009 May; 259(3):133-9. PubMed ID: 19428953 [TBL] [Abstract][Full Text] [Related]
12. Toxicological considerations of acetylcholinesterase reactivators. Voicu V; Rădulescu FŞ; Medvedovici A Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):31-50. PubMed ID: 23176543 [TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Worek F; Thiermann H; Szinicz L; Eyer P Biochem Pharmacol; 2004 Dec; 68(11):2237-48. PubMed ID: 15498514 [TBL] [Abstract][Full Text] [Related]
14. In vivo oxime administration does not influence Ellman acetylcholinesterase assay results. Guarisco JA; O'Donnell JC; Skovira JW; McDonough JH; Shih TM Toxicol Mech Methods; 2009 Sep; 19(6-7):379-85. PubMed ID: 19778238 [TBL] [Abstract][Full Text] [Related]
15. Increasing oxime efficacy by blood-brain barrier modulation. Joosen MJ; van der Schans MJ; van Dijk CG; Kuijpers WC; Wortelboer HM; van Helden HP Toxicol Lett; 2011 Sep; 206(1):67-71. PubMed ID: 21600273 [TBL] [Abstract][Full Text] [Related]
16. The influence of combinations of oximes on the reactivating and therapeutic efficacy of antidotal treatment of tabun poisoning in rats and mice. Kassa J; Karasova JZ; Pavlikova R; Misik J; Caisberger F; Bajgar J J Appl Toxicol; 2010 Mar; 30(2):120-4. PubMed ID: 19746406 [TBL] [Abstract][Full Text] [Related]
17. Evaluation and computational characterization of the facilitated transport of Glc carbon C-1 oxime reactivators across a blood brain barrier model. Bhonsle JB; Causey R; Oyler BL; Bartolucci C; Lamba D; Pesaresi A; Bhamare NK; Soojhawon I; Garcia GE Chem Biol Interact; 2013 Mar; 203(1):129-34. PubMed ID: 23073172 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of medical countermeasures against organophosphorus compounds: the value of experimental data and computer simulations. Worek F; Aurbek N; Herkert NM; John H; Eddleston M; Eyer P; Thiermann H Chem Biol Interact; 2010 Sep; 187(1-3):259-64. PubMed ID: 19917271 [TBL] [Abstract][Full Text] [Related]
20. Analysis of inhibition, reactivation and aging kinetics of highly toxic organophosphorus compounds with human and pig acetylcholinesterase. Aurbek N; Thiermann H; Szinicz L; Eyer P; Worek F Toxicology; 2006 Jul; 224(1-2):91-9. PubMed ID: 16720069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]